Financial Impact of Hidradenitis Suppurativa in Spain - Scorecard - MDSpire

Financial Impact of Hidradenitis Suppurativa in Spain

  • By

  • Eva Vilarrasa

  • Joaquín Borrás-Blasco

  • Silvia Lobo-Benito

  • Marta Loro-Pérez

  • Marta Garcia Núñez-García

  • Juan Oliva-Moreno

  • David Palacios-Martínez

  • Félix Rubial-Bernárdez

  • Yoana Ivanova-Markova

  • Mathilde Daheron

  • Javier Bellas

  • Antonio Martorell

  • February 22, 2026

  • 0 min

Share

Clinical Scorecard: Financial Impact of Hidradenitis Suppurativa in Spain

At a Glance

CategoryDetail
Condition
Key MechanismsExpand to include all key symptoms and impacts on quality of life.
Target Population
Care Setting

Key Highlights

  • add

Guideline-Based Recommendations

Diagnosis

    Management

    • A
    • d
    • d
    • m
    • o
    • r
    • e
    • d
    • e
    • t
    • a
    • i
    • l
    • e
    • d
    • m
    • a
    • n
    • a
    • g
    • e
    • m
    • e
    • n
    • t
    • s
    • t
    • r
    • a
    • t
    • e
    • g
    • i
    • e
    • s
    • a
    • n
    • d
    • t
    • r
    • e
    • a
    • t
    • m
    • e
    • n
    • t
    • o
    • p
    • t
    • i
    • o
    • n
    • s
    • .

    Monitoring & Follow-up

      Risks

        Patient & Prescribing Data

        Clarify the significance and roles of biologics in treatment.

        Clinical Best Practices

        • add

        References

        Original Source(s)

        Related Content